"Relatively large" investment to double tablet production at ALK
The production of ALK’s main product - tablet vaccines for the treatment of allergies - is to be accelerated.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
ALK CEO sees growth opportunities in adrenaline pen market
For subscribers
ALK "can continue to achieve double-digit growth," says CEO
For subscribers